Christine M. Klaskin
Net Worth
Last updated:
What is Christine M. Klaskin net worth?
The estimated net worth of Ms. Christine M. Klaskin is at least $6,499,482 as of 10 Sep 2021. She owns shares worth $428,058 as insider, has earned $263,904 from insider trading and has received compensation worth at least $5,807,520 in Agenus Inc..
What is the salary of Christine M. Klaskin?
Ms. Christine M. Klaskin salary is $362,970 per year as Vice President of Fin., Principal Financial Officer & Principal Accounting Officer in Agenus Inc..
How old is Christine M. Klaskin?
Ms. Christine M. Klaskin is 59 years old, born in 1966.
What stocks does Christine M. Klaskin currently own?
As insider, Ms. Christine M. Klaskin owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Agenus Inc. (AGEN) | Vice President of Fin., Principal Financial Officer & Principal Accounting Officer | 93,056 | $4.6 | $428,058 |
What does Agenus Inc. do?
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Christine M. Klaskin insider trading
Agenus Inc.
Ms. Christine M. Klaskin has made 17 insider trades between 2009-2021, according to the Form 4 filled with the SEC.
The largest trade she's ever made was exercising 78,868 units of AGEN stock on 20 Jan 2010. As of 10 Sep 2021 she still owns at least 93,056 units of AGEN stock.
Agenus key executives
Agenus Inc. executives and other stock owners filed with the SEC:
- Dr. Garo H. Armen Ph.D. (72) Founder, Executive Chairman & Chief Executive Officer
- Ms. Christine M. Klaskin (59) Vice President of Fin., Principal Financial Officer & Principal Accounting Officer